| CD155 Expression in Acute Myeloid Leukemia (NCT06369662) | Assiut University | 2022-07-01 |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (NCT05143840) | University of Alabama at Birmingham | 2022-04-22 |
| Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation (NCT05282459) | Tian Yi Zhang | 2022-01-12 |
| A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy (NCT04748848) | Celgene | 2021-10-14 |
| Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (NCT04789655) | Celgene | 2021-06-16 |
| A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors (NCT04598789) | Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna | 2020-07-07 |
| Endogenous Retroviruses in Acute Myeloid Leukemia (NCT04406207) | Hospices Civils de Lyon | 2020-06-01 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML (NCT04310592) | Celularity Incorporated | 2020-03-12 |
| Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia (NCT04272125) | Chongqing Precision Biotech Co., Ltd | 2019-12-01 |
| Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease (NCT04039100) | Rigshospitalet, Denmark | 2019-10-01 |
| CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia (NCT04265963) | Chongqing Precision Biotech Co., Ltd | 2019-09-01 |
| A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML (NCT03417427) | Xuejie Jiang | 2018-02-01 |
| Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS (NCT03066648) | Novartis Pharmaceuticals | 2017-07-06 |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG (NCT02916979) | Dartmouth-Hitchcock Medical Center | 2016-09-06 |
| Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease (NCT02370888) | University of Florida | 2016-05-16 |
| High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML (NCT03080922) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2016-03-01 |
| An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (NCT02577406) | Celgene | 2015-12-30 |
| A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia (NCT02538965) | Celgene | 2015-11-19 |
| Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies (NCT02333838) | Assistance Publique - Hôpitaux de Paris | 2015-05-01 |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients (NCT01511289) | Il-Yang Pharm. Co., Ltd. | 2011-08-01 |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders (NCT01392989) | Everett Meyer | 2011-03-01 |
| Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia (NCT01050036) | Asan Medical Center | 2010-01-11 |
| Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI (NCT01602952) | Il-Yang Pharm. Co., Ltd. | 2008-07-01 |
| Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias (NCT01144793) | Stanford University | 2008-04-01 |
| Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia (NCT00611247) | Bruno C. Medeiros | 2007-12-01 |
| Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML (NCT00568633) | Stanford University | 2007-08-01 |
| Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia (NCT00512083) | Antisoma Research | 2007-07-01 |
| T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation (NCT00306332) | Radboud University Medical Center | 2006-03-01 |
| A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia (NCT00233909) | Kanisa Pharmaceuticals | 2005-10-01 |
| Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT00129168) | Kanisa Pharmaceuticals | 2005-08-01 |
| Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes (NCT00451997) | M.D. Anderson Cancer Center | 2004-03-01 |
| Analyses of Human Samples Collected in Clinical Trials (NCT00339664) | National Cancer Institute (NCI) | 2003-07-02 |
| Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation (NCT00030186) | Cephalon | 2002-01-01 |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS (NCT00025662) | National Heart, Lung, and Blood Institute (NHLBI) | 2001-05-01 |